WO2005023198A3 - Modafinil compositions - Google Patents

Modafinil compositions Download PDF

Info

Publication number
WO2005023198A3
WO2005023198A3 PCT/US2004/029013 US2004029013W WO2005023198A3 WO 2005023198 A3 WO2005023198 A3 WO 2005023198A3 US 2004029013 W US2004029013 W US 2004029013W WO 2005023198 A3 WO2005023198 A3 WO 2005023198A3
Authority
WO
WIPO (PCT)
Prior art keywords
modafinil
modulated
modafinil compositions
enantiomerically
compositions
Prior art date
Application number
PCT/US2004/029013
Other languages
French (fr)
Other versions
WO2005023198A2 (en
Inventor
Magali Bourghol Hickey
Matthew Peterson
Orn Almarsson
Mark Oliveira
Original Assignee
Transform Pharmaceuticals Inc
Magali Bourghol Hickey
Matthew Peterson
Orn Almarsson
Mark Oliveira
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Application filed by Transform Pharmaceuticals Inc, Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira filed Critical Transform Pharmaceuticals Inc
Priority to CN2004800319825A priority Critical patent/CN1874993B/en
Priority to KR1020067004425A priority patent/KR101184797B1/en
Priority to US10/570,405 priority patent/US7566805B2/en
Priority to MXPA06002507A priority patent/MXPA06002507A/en
Priority to CA2534664A priority patent/CA2534664C/en
Priority to AU2004270238A priority patent/AU2004270238B2/en
Priority to BRPI0413777-9A priority patent/BRPI0413777A/en
Priority to EP20040783308 priority patent/EP1670753A4/en
Priority to JP2006525508A priority patent/JP4842819B2/en
Priority to NZ545133A priority patent/NZ545133A/en
Priority to EA200601390A priority patent/EA009949B1/en
Priority to PCT/US2005/002782 priority patent/WO2005077894A1/en
Priority to CN2005800041104A priority patent/CN1980888B/en
Priority to US10/587,086 priority patent/US20090018202A1/en
Priority to EP05712282A priority patent/EP1718607A4/en
Priority to BRPI0507455-0A priority patent/BRPI0507455A/en
Priority to CA002556106A priority patent/CA2556106A1/en
Priority to EP10001997A priority patent/EP2292213A1/en
Priority to JP2006552169A priority patent/JP4917441B2/en
Priority to AU2005212229A priority patent/AU2005212229B2/en
Publication of WO2005023198A2 publication Critical patent/WO2005023198A2/en
Publication of WO2005023198A3 publication Critical patent/WO2005023198A3/en
Priority to IL173575A priority patent/IL173575A0/en
Priority to NO20060669A priority patent/NO20060669L/en
Priority to IL176934A priority patent/IL176934A/en
Priority to NO20063957A priority patent/NO20063957L/en
Priority to IL199140A priority patent/IL199140A/en
Priority to US12/708,998 priority patent/US8338646B2/en
Priority to US13/706,835 priority patent/US8809586B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid

Abstract

Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.
PCT/US2004/029013 2000-07-15 2004-09-04 Modafinil compositions WO2005023198A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
CN2004800319825A CN1874993B (en) 2003-09-04 2004-09-04 Modafinil compositionsc
KR1020067004425A KR101184797B1 (en) 2003-09-04 2004-09-04 Modafinil compositions
US10/570,405 US7566805B2 (en) 2003-09-04 2004-09-04 Modafinil compositions
MXPA06002507A MXPA06002507A (en) 2003-09-04 2004-09-04 Modafinil compositions.
CA2534664A CA2534664C (en) 2003-09-04 2004-09-04 Modafinil compositions
AU2004270238A AU2004270238B2 (en) 2003-09-04 2004-09-04 Modafinil compositions
BRPI0413777-9A BRPI0413777A (en) 2003-09-04 2004-09-04 modafinil compositions
EP20040783308 EP1670753A4 (en) 2003-09-04 2004-09-04 Modafinil compositions
JP2006525508A JP4842819B2 (en) 2003-09-04 2004-09-04 Modafinil composition
NZ545133A NZ545133A (en) 2003-09-04 2004-09-04 Modafinil compositions
AU2005212229A AU2005212229B2 (en) 2004-02-06 2005-02-01 Modafinil compositions
PCT/US2005/002782 WO2005077894A1 (en) 2004-02-06 2005-02-01 Modafinil compositions
JP2006552169A JP4917441B2 (en) 2004-02-06 2005-02-01 Modafinil composition
EA200601390A EA009949B1 (en) 2004-02-06 2005-02-01 Modafinil compositions
CN2005800041104A CN1980888B (en) 2004-02-06 2005-02-01 Modafinil compositions
US10/587,086 US20090018202A1 (en) 2004-02-06 2005-02-01 Modafinil compositions
EP05712282A EP1718607A4 (en) 2004-02-06 2005-02-01 Modafinil compositions
BRPI0507455-0A BRPI0507455A (en) 2000-07-15 2005-02-01 composition, methods of making a r - (-) - modafinil polymorph, making 2: 1 of r - (-) - modafinil: s - (+) - modafinil, making forms iii, iv and v of r - (-) modafinil and treatment of an individual suffering from diseases, and r - (-) - modafinil solvate, and methods of treating an individual suffering from excessive daytime sleep associated with narcolepsy, narcolepsy or sleep apnea and attention deficit hyperactivity disorder (adhd)
CA002556106A CA2556106A1 (en) 2004-02-06 2005-02-01 Modafinil compositions
EP10001997A EP2292213A1 (en) 2004-02-06 2005-02-01 Compositions comprising a polymorphic form of armodafinil
IL173575A IL173575A0 (en) 2003-09-04 2006-02-07 Modafinil compositions
NO20060669A NO20060669L (en) 2003-09-11 2006-02-10 Modafinilsammensetninger
IL176934A IL176934A (en) 2004-02-06 2006-07-18 Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd)
NO20063957A NO20063957L (en) 2004-02-06 2006-09-05 Modafinilsammensetninger
IL199140A IL199140A (en) 2003-09-04 2009-06-03 Modafinil compositions
US12/708,998 US8338646B2 (en) 2004-02-06 2010-02-19 Modafinil compositions
US13/706,835 US8809586B2 (en) 2004-02-06 2012-12-06 Modafinil compositions

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US32777203A 2003-09-04 2003-09-04
USUS03/27772 2003-09-04
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/660,202 2003-09-11
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06
US40628804A 2004-02-26 2004-02-26
USUS04/06288 2004-02-26
US56041104P 2004-04-06 2004-04-06
US60/560,411 2004-04-06
US57341204P 2004-05-21 2004-05-21
US60/573,412 2004-05-21
US57917604P 2004-06-12 2004-06-12
US60/579,176 2004-06-12
US58199204P 2004-06-22 2004-06-22
US60/581,992 2004-06-22
US58675204P 2004-07-09 2004-07-09
US60/586,752 2004-07-09
US58823604P 2004-07-15 2004-07-15
US60/588,236 2004-07-15

Publications (2)

Publication Number Publication Date
WO2005023198A2 WO2005023198A2 (en) 2005-03-17
WO2005023198A3 true WO2005023198A3 (en) 2005-07-14

Family

ID=34280325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029013 WO2005023198A2 (en) 2000-07-15 2004-09-04 Modafinil compositions

Country Status (6)

Country Link
KR (1) KR101184797B1 (en)
AU (1) AU2004270238B2 (en)
CA (1) CA2534664C (en)
MX (1) MXPA06002507A (en)
NZ (1) NZ545133A (en)
WO (1) WO2005023198A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
FR2849029B1 (en) 2002-12-20 2005-03-18 Lafon Labor PROCESS FOR THE PREPARATION AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
ATE483455T1 (en) * 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc MIXED CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007013962A2 (en) * 2005-07-21 2007-02-01 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
ITMI20051971A1 (en) * 2005-10-18 2007-04-19 Dipharma Spa PROCEDURE FOR THE PREPARATION OF - MODAFINIL
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
WO2008075736A1 (en) 2006-12-21 2008-06-26 Astellas Pharma Inc. Method for producing c-glycoside derivative and synthetic intermediate thereof
WO2009025791A2 (en) 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US8871793B2 (en) * 2009-12-23 2014-10-28 Nuformix Limited Metaxalone cocrystals
KR102372908B1 (en) * 2021-09-27 2022-03-10 유니셀랩 주식회사 Novel co-crystal of pelubiprofen/mandelic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002056915A2 (en) * 2000-12-19 2002-07-25 Cephalon, Inc. Complex of modafinil and cyclodextrin
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040019211A1 (en) * 2002-05-31 2004-01-29 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (en) * 1986-01-31 1988-07-22 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE
EP1608339B8 (en) * 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002056915A2 (en) * 2000-12-19 2002-07-25 Cephalon, Inc. Complex of modafinil and cyclodextrin
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20030224006A1 (en) * 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040019211A1 (en) * 2002-05-31 2004-01-29 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1670753A4 *

Also Published As

Publication number Publication date
CA2534664C (en) 2012-10-30
AU2004270238A1 (en) 2005-03-17
WO2005023198A2 (en) 2005-03-17
CA2534664A1 (en) 2005-03-17
KR101184797B1 (en) 2012-09-20
MXPA06002507A (en) 2006-06-20
NZ545133A (en) 2009-12-24
AU2004270238B2 (en) 2010-07-29
KR20060128831A (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2005023198A3 (en) Modafinil compositions
SE0401971D0 (en) Piperidne derivatives
WO2005123076A3 (en) Pharmaceutical compositions
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2006132647A3 (en) Antimicrobial copolymers and uses thereof
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
HRP20060240T3 (en) Intranasal formulation of rotigotine
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
TW200716628A (en) Novel compounds
PL356904A1 (en) Pharmaceutical compositions
CA2556514A1 (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
SE0401970D0 (en) Novel compounds
IS8430A (en) Medicines containing (2R) -2-propyl octanoic acid as the active ingredient
WO2004069146A3 (en) L-dopa amide derivatives and uses thereof
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
DE60142913D1 (en) DRUG SOLUTIONS CONTAIN MODAFINIL COMPOUNDS
WO2005065639A3 (en) Novel pharmaceutical compositions
BRPI0413777A (en) modafinil compositions
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
SE0001916D0 (en) Novel formulation
WO2006044548A3 (en) Clopidogrel compositions
NO20060669L (en) Modafinilsammensetninger
WO2004106329A3 (en) Novel antiinfective compounds and their pharmaceutical compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480031982.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2534664

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 173575

Country of ref document: IL

Ref document number: 545133

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 371/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002507

Country of ref document: MX

Ref document number: 2004270238

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007021510

Country of ref document: US

Ref document number: 2006525508

Country of ref document: JP

Ref document number: 10570405

Country of ref document: US

Ref document number: 1020067004425

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004270238

Country of ref document: AU

Date of ref document: 20040904

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004270238

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004783308

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004783308

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413777

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067004425

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10570405

Country of ref document: US